How Delaying Cancer Treatment Impacts Survival: Eugene Cone, MD

In a study published this past week in JAMA Network Open, Eugene Cone, MD, and colleagues found that a longer time to treatment initiation negatively impacts survival in patients with breast, prostate, colon, and lung cancers, a finding that is particularly relevant with the deferral of treatment during the COVID-19 pandemic. In this interview, Dr. Cone, a clinical fellow in surgery at Massachusetts General Hospital, speaks with i3 Health about the significance of these results and shares advice...
Continue reading

Jaume Mora, MD, PhD: Naxitamab Approval for High-Risk Neuroblastoma in the Bone or Bone Marrow

Recently, the FDA approved naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow. In this interview, Jaume Mora, MD, PhD, Scientific Director of Oncology and Hematology at Sant Joan de Déu Barcelona Children's Hospital and lead investigator of one of the trials on which the approval was based, speaks with i3 Health about the benefits of naxitamab for patients with relapsed/r...
Continue reading

Thomas Hope, MD: Gallium 68 PSMA-11 Approval for PSMA-Targeted PET Imaging of Prostate Cancer

The FDA recently approved gallium (Ga) 68 PSMA-11, a radioactive diagnostic agent, for prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging of patients with recurrent prostate cancer. Ga 68 PSMA-11, the approval of which was granted to the University of California San Francisco (UCSF) and the University of California Los Angeles (UCLA), is the first agent to be approved specifically for the detection of PSMA-positive lesions. In this interview with i3 Hea...
Continue reading

Hagop Kantarjian, MD: Inotuzumab Ozogamicin for Relapsed/Refractory Ph-Positive Acute Lymphoblastic Leukemia

Among patients with relapsed/refractory acute lymphoblastic leukemia (ALL), those with Philadelphia chromosome (Ph)-positive disease experience a higher rate of relapse and poorer chances of long-term survival. According to results of the phase 3 INO-VATE trial recently published in Cancer, inotuzumab ozogamicin, a humanized anti-CD22 monoclonal antibody, achieved high rates of response, remission, and progression-free survival in patients with this disease. In this interview with i3 Health, Hag...
Continue reading

Vitamin D Supplements for Reducing Advanced Cancer Risk: Paulette Chandler, MD, MPH

In a study recently published in JAMA Network Open, a team of investigators led by Paulette Chandler, MD, MPH, found that vitamin D supplementation is associated with a decreased risk of developing advanced cancer, particularly among individuals with a normal body mass index (BMI). In this interview with i3 Health, Dr. Chandler, an Assistant Professor of Medicine at Harvard Medical School, discusses the significance of these results and the ongoing research investigating vitamin D supplementatio...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.